Zhejiang Wolwo Bio-Pharma - Public Comps and Valuation Multiples

Zhejiang Wolwo Bio-Pharma Overview

About Zhejiang Wolwo Bio-Pharma

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd is a Chinese bio-pharmaceutical company. It is engaged in the research development, production and sales of allergic diseases diagnosis and treatment products. The product portfolio of the company covers dust mites drops, dust mites skin prick diagnosis kit, silk, and others.

Founded

2002

HQ

Employees

n/a

Website

wolwobiotech.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $155M

LTM EBITDA $70.0M

EV

$2.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Zhejiang Wolwo Bio-Pharma Financials

As of December 2025, Zhejiang Wolwo Bio-Pharma reported last 12-month revenue of $155M and EBITDA of $70.0M.

In the same period, Zhejiang Wolwo Bio-Pharma generated $147M in LTM gross profit and $57.6M in net income.

See Zhejiang Wolwo Bio-Pharma valuation multiples based on analyst estimates

Zhejiang Wolwo Bio-Pharma P&L

In the most recent fiscal year, Zhejiang Wolwo Bio-Pharma reported revenue of $132M and EBITDA of $59.6M.

Zhejiang Wolwo Bio-Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Zhejiang Wolwo Bio-Pharma valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$155M	XXX	$132M	XXX	XXX	XXX
Gross Profit	$147M	XXX	$126M	XXX	XXX	XXX
Gross Margin	95%	XXX	95%	XXX	XXX	XXX
EBITDA	$70.0M	XXX	$59.6M	XXX	XXX	XXX
EBITDA Margin	45%	XXX	45%	XXX	XXX	XXX
EBIT	$65.3M	XXX	$47.5M	XXX	XXX	XXX
EBIT Margin	42%	XXX	36%	XXX	XXX	XXX
Net Profit	$57.6M	XXX	$45.4M	XXX	XXX	XXX
Net Margin	37%	XXX	34%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Zhejiang Wolwo Bio-Pharma including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $155M. EBITDA for the last twelve months was $70.0M. In the most recent fiscal year, Zhejiang Wolwo Bio-Pharma achieved $132M in revenue and $59.6M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$155M	Analyst estimates available to subscribers	$132M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$147M	Analyst estimates available to subscribers	$126M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	95.2% gross margin	Analyst estimates available to subscribers	95.2% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$70.0M	Analyst estimates available to subscribers	$59.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	45.3% EBITDA margin	Analyst estimates available to subscribers	45.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$65.3M	Analyst estimates available to subscribers	$47.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	42.3% EBIT margin	Analyst estimates available to subscribers	35.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$57.6M	Analyst estimates available to subscribers	$45.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	37.3% net profit margin	Analyst estimates available to subscribers	34.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Zhejiang Wolwo Bio-Pharma

This financial data table provides comprehensive performance metrics for Zhejiang Wolwo Bio-Pharma, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Zhejiang Wolwo Bio-Pharma generated $155M in revenue over the last twelve months.
The company achieved $70.0M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $147M.
Net income over the last twelve months reached $57.6M.

Fiscal Year Performance

In the most recent fiscal year, Zhejiang Wolwo Bio-Pharma reported $132M in total revenue.
Fiscal year EBITDA was $59.6M.
The company maintained a gross profit margin of 95.2% in the most recent fiscal year.
EBITDA margin for the fiscal year was 45.1%.
Net profit margin reached 34.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Zhejiang Wolwo Bio-Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Zhejiang Wolwo Bio-Pharma Stock Performance

Zhejiang Wolwo Bio-Pharma has current market cap of CNY 16.0B (or $2.3B), and EV of CNY 14.7B (or $2.1B).

Market Cap Evolution

Zhejiang Wolwo Bio-Pharma Stock Data

As of January 16, 2026, Zhejiang Wolwo Bio-Pharma's stock price is CNY 31 (or $4).

See Zhejiang Wolwo Bio-Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.1B	$2.3B	XXX	XXX	XXX	XXX	$0.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Zhejiang Wolwo Bio-Pharma Valuation Multiples

Zhejiang Wolwo Bio-Pharma's trades at 13.6x EV/Revenue multiple, and 29.9x EV/EBITDA.

See valuation multiples for Zhejiang Wolwo Bio-Pharma and 15K+ public comps

Zhejiang Wolwo Bio-Pharma Financial Valuation Multiples

As of January 16, 2026, Zhejiang Wolwo Bio-Pharma has market cap of $2.3B and EV of $2.1B.

Equity research analysts estimate Zhejiang Wolwo Bio-Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Zhejiang Wolwo Bio-Pharma has a P/E ratio of 39.7x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$2.3B	XXX	$2.3B	XXX	XXX	XXX
EV (current)	$2.1B	XXX	$2.1B	XXX	XXX	XXX
EV/Revenue	13.6x	XXX	13.6x	XXX	XXX	XXX
EV/EBITDA	29.9x	XXX	29.9x	XXX	XXX	XXX
EV/EBIT	32.1x	XXX	32.1x	XXX	XXX	XXX
EV/Gross Profit	14.3x	XXX	n/a	XXX	XXX	XXX
P/E	39.7x	XXX	39.7x	XXX	XXX	XXX
EV/FCF	n/a	XXX	101.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Zhejiang Wolwo Bio-Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Zhejiang Wolwo Bio-Pharma Margins & Growth Rates

Zhejiang Wolwo Bio-Pharma's last 12 month revenue growth is 19%

Zhejiang Wolwo Bio-Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Zhejiang Wolwo Bio-Pharma's rule of 40 is 64% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Zhejiang Wolwo Bio-Pharma's rule of X is 93% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Zhejiang Wolwo Bio-Pharma and other 15K+ public comps

Zhejiang Wolwo Bio-Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	19%	XXX	19%	XXX	XXX	XXX
EBITDA Margin	45%	XXX	45%	XXX	XXX	XXX
EBITDA Growth	21%	XXX	13%	XXX	XXX	XXX
Rule of 40	64%	XXX	64%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	93%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	23%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	13%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	59%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial